Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can talking to a nurse protect your brain during chemo?

NCT ID NCT05538000

Symptom relief Sponsor: Institut de Cancérologie de Lorraine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 02, 2026 · Updated 5 times

Summary

This study tests whether a personalized support program led by a nurse can help prevent memory and thinking problems that often occur after chemotherapy in women with non-metastatic breast cancer. Fifty women will receive regular face-to-face and telephone interviews over 9 months. The main goal is to see if the program is feasible, not yet if it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized support program by a nurse (face-to-face and telephone interviews)
What this could lead to
If successful, this could lead to a practical way to help breast cancer patients avoid or reduce cognitive problems after chemotherapy, improving their quality of life.
What could go wrong
This is a small, early feasibility study with only 50 participants and no control group. It cannot prove the program works, only that it might be possible to run a larger trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65; * WHO 0 to 1; * Patient newly diagnosed with breast cancer (unilateral or bilateral); * Patient with a MoCA score not revealing proven cognitive disorders (MoCA ≥ 26/30 and a QPC score \<3, without a "YES" answer to question 5 and without 2 "YES" answers to questions A, 4, 5, 7, 8 of the questionnaire); * Patient to receive adjuvant or neo-adjuvant chemotherapy; * Patient having understood, signed and dated the consent form * Affiliated to a social security system Exclusion Criteria: * Patient with a cancer concomitant with breast cancer and/or metastatic breast cancer; * Patients with previous or ongoing carcinological treatment; * Patient with a major cognitive disorder or a significant cognitive complaint (according to MoCA \< 26/30 and QPC \>3 with "YES" answer to question 5 and with 2 "YES" answers to questions A, 4, 5, 7, 8 of the questionnaire) or neurological sequelae (epilepsy or neurodegenerative disease); * Patients who are hearing impaired, visually impaired, or unable to read or speak French * Patient deprived of liberty (including curatorship and guardianship); * Pregnant woman; * Man.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for No metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

No metastatic breast cancer

Contacts and locations

Locations

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, Vandoeuvres Les Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.